<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;utm_source=Chrome&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 02 Jan 2025 18:14:41 +0000</lastbuilddate>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Heterogeneity of Apolipoprotein B Levels Among Hispanic or Latino Individuals Residing in the US</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745752/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this cohort study among participants from the HCHS/SOL, elevated apoB was present in one-quarter of a diverse cohort study of Hispanic or Latino individuals who were at intermediate or high predicted ASCVD risk. Differences in apoB distribution among Hispanic or Latino individuals may have important implications for apoB's use in ASCVD risk assessment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 2. doi: 10.1001/jamacardio.2024.4789. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Apolipoprotein B (apoB) distribution and its implications as an atherosclerotic cardiovascular disease (ASCVD) risk-enhancing factor among individuals of diverse Hispanic or Latino backgrounds have not been described.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To describe the distribution of apoB in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) cohort and to characterize associations of baseline sociodemographic and clinical variables with apoB and self-identified Hispanic or Latino background.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The HCHS/SOL was a prospective, population-based cohort study of diverse Hispanic or Latino adults living in the US who were recruited and screened between March 2008 and June 2011. Sampling weights were used to generate a population-based sample of Hispanic or Latino participants aged 18 to 74 years who resided in 4 US metropolitan areas (Bronx, New York; Chicago, Illinois; Miami, Florida; and San Diego, California). ApoB concentration was measured in participants from the HCHS/SOL, and apoB tertiles were compared across demographic groups, including self-identified Hispanic or Latino background. Median percentage continental genetic ancestry (West African, Amerindian, and European) was compared across apoB tertiles.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: ApoB measured in mg/dL from serum or plasma using an immunoturbidimetric assay.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: ApoB tertiles were determined, and traditional lipids were evaluated across apoB tertiles. ApoB and traditional lipid measurements were assessed across ASCVD risk categories. Additionally, scatterplots were created to observe correlations between apoB and low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Overall mean (SD) apoB concentration was 99.8 (0.4) mg/dL, with male participants displaying significantly higher mean levels than female participants (102.4 vs 97.4 mg/dL, respectively). Mean (SD) participant age was 41.1 (0.8) years, and 8376 participants (51.9%) were female. ApoB levels were higher among older age groups. There was significant heterogeneity in mean apoB concentrations across self-identified Hispanic or Latino background groups, ranging from 95.1 mg/dL in Dominican individuals to 104.8 mg/dL in Cuban individuals. The prevalence of elevated apoB (≥130 mg/dL) was greater across higher predicted ASCVD risk categories. Among participants with a 10-year predicted ASCVD risk of 7.5% or higher, 26.5% had an elevated apoB. Median West African ancestry was lower across higher tertiles of apoB.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cohort study among participants from the HCHS/SOL, elevated apoB was present in one-quarter of a diverse cohort study of Hispanic or Latino individuals who were at intermediate or high predicted ASCVD risk. Differences in apoB distribution among Hispanic or Latino individuals may have important implications for apoB's use in ASCVD risk assessment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745752/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39745752</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4789>10.1001/jamacardio.2024.4789</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745752</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Leandro Slipczuk</dc:creator>
<dc:creator>Toshiki Kuno</dc:creator>
<dc:creator>Santica Marcovina</dc:creator>
<dc:creator>Katrina Swett</dc:creator>
<dc:creator>Kate K Orroth</dc:creator>
<dc:creator>J Antonio G López</dc:creator>
<dc:creator>Shia T Kent</dc:creator>
<dc:creator>John N Booth</dc:creator>
<dc:creator>Robert Kaplan</dc:creator>
<dc:creator>Daniela Sotres-Alvarez</dc:creator>
<dc:creator>Bharat Thyagarajan</dc:creator>
<dc:creator>Tamar Sofer</dc:creator>
<dc:creator>Martha L Daviglus</dc:creator>
<dc:creator>Gregory A Talavera</dc:creator>
<dc:creator>Parag H Joshi</dc:creator>
<dc:creator>Carlos J Rodriguez</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Heterogeneity of Apolipoprotein B Levels Among Hispanic or Latino Individuals Residing in the US</dc:title>
<dc:identifier>pmid:39745752</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4789</dc:identifier>
</item>
<item>
<title>Sex Differences in the Effectiveness and Safety of Aspirin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745729/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 2. doi: 10.1001/jamacardio.2024.4806. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745729/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39745729</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4806>10.1001/jamacardio.2024.4806</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745729</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Marko Lucijanic</dc:creator>
<dc:creator>Eugen Javor</dc:creator>
<dc:creator>Marko Skelin</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sex Differences in the Effectiveness and Safety of Aspirin</dc:title>
<dc:identifier>pmid:39745729</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4806</dc:identifier>
</item>
<item>
<title>Artificial Intelligence-Enhanced Electrocardiography for Prediction of Incident Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745684/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results suggest that AIRE-HTN, an AI-ECG model, can predict incident hypertension and identify patients at risk of hypertension-related adverse events, beyond conventional clinical risk factors.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 2. doi: 10.1001/jamacardio.2024.4796. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Hypertension underpins significant global morbidity and mortality. Early lifestyle intervention and treatment are effective in reducing adverse outcomes. Artificial intelligence-enhanced electrocardiography (AI-ECG) has been shown to identify a broad spectrum of subclinical disease and may be useful for predicting incident hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To develop an AI-ECG risk estimator (AIRE) to predict incident hypertension (AIRE-HTN) and stratify risk for hypertension-associated adverse outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a development and external validation prognostic cohort study conducted at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, a secondary care setting. External validation was conducted in the UK Biobank (UKB), a UK-based volunteer cohort. AIRE-HTN was trained and tested to predict incident hypertension using routinely collected ECGs from patients at BIDMC between 2014 and 2023. The algorithm was then evaluated to risk stratify patients for hypertension- associated adverse outcomes and externally validated on UKB data between 2014 and 2022 for both incident hypertension and risk stratification.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: AIRE-HTN, which uses a residual convolutional neural network architecture with a discrete-time survival loss function, was trained to predict incident hypertension.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: AIRE-HTN was trained on 1 163 401 ECGs from 189 539 patients (mean [SD] age, 57.7 [18.7] years; 98 747 female [52.1%]) at BIDMC. A total of 19 423 BIDMC patients composed the test set and were evaluated for incident hypertension. From the UKB, AIRE-HTN was tested on 65 610 ECGs from same number of participants (mean [SD] age, 65.4 [7.9] years; 33 785 female [51.5%]). A total of 35 806 UKB patients were evaluated for incident hypertension. AIRE-HTN predicted incident hypertension (BIDMC: n = 6446 [33%] events; C index, 0.70; 95% CI, 0.69-0.71; UKB: n = 1532 [4%] events; C index, 0.70; 95% CI, 0.69-0.71). Performance was maintained in individuals without left ventricular hypertrophy and those with normal ECGs (C indices, 0.67-0.72). AIRE-HTN was significantly additive to existing clinical risk factors in predicting incident hypertension (continuous net reclassification index, BIDMC: 0.44; 95% CI, 0.33-0.53; UKB: 0.32; 95% CI, 0.23-0.37). In adjusted Cox models, AIRE-HTN score was an independent predictor of cardiovascular death (hazard ratio [HR] per standard deviation, 2.24; 95% CI, 1.67-3.00) and stratified risk for heart failure (HR, 2.60; 95% CI, 2.22-3.04), myocardial infarction (HR, 3.13; 95% CI, 2.55-3.83), ischemic stroke (HR, 1.23; 95% CI, 1.11-1.37), and chronic kidney disease (HR, 1.89; 95% CI, 1.68-2.12), beyond traditional risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results suggest that AIRE-HTN, an AI-ECG model, can predict incident hypertension and identify patients at risk of hypertension-related adverse events, beyond conventional clinical risk factors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745684/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39745684</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4796>10.1001/jamacardio.2024.4796</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745684</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Arunashis Sau</dc:creator>
<dc:creator>Joseph Barker</dc:creator>
<dc:creator>Libor Pastika</dc:creator>
<dc:creator>Ewa Sieliwonczyk</dc:creator>
<dc:creator>Konstantinos Patlatzoglou</dc:creator>
<dc:creator>Kathryn A McGurk</dc:creator>
<dc:creator>Nicholas S Peters</dc:creator>
<dc:creator>Declan P O'Regan</dc:creator>
<dc:creator>James S Ware</dc:creator>
<dc:creator>Daniel B Kramer</dc:creator>
<dc:creator>Jonathan W Waks</dc:creator>
<dc:creator>Fu Siong Ng</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Artificial Intelligence-Enhanced Electrocardiography for Prediction of Incident Hypertension</dc:title>
<dc:identifier>pmid:39745684</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4796</dc:identifier>
</item>
<item>
<title>Sex Differences in the Effectiveness and Safety of Aspirin-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745683/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 2. doi: 10.1001/jamacardio.2024.4809. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745683/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39745683</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4809>10.1001/jamacardio.2024.4809</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745683</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Catherine P Benziger</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sex Differences in the Effectiveness and Safety of Aspirin-Reply</dc:title>
<dc:identifier>pmid:39745683</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4809</dc:identifier>
</item>
<item>
<title>Navigating the 2024 ESC Hypertension Guidelines: What Is New, Context, and Future Directions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745405/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Dec 30:S0735-1097(24)10475-5. doi: 10.1016/j.jacc.2024.10.114. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745405/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39745405</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.114>10.1016/j.jacc.2024.10.114</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745405</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Yuan Lu</dc:creator>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Navigating the 2024 ESC Hypertension Guidelines: What Is New, Context, and Future Directions</dc:title>
<dc:identifier>pmid:39745405</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.114</dc:identifier>
</item>
<item>
<title>Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39745404/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our analysis of a large pooled dataset from 4 clinical trials, including >;16,900 patients with HFmrEF/HFpEF, indicates a J-shaped relationship between both SBP and PP and cardiovascular risk. The lowest risk was observed at SBP levels between 120 and 130 mm Hg and PP values between 50 and 60 mm Hg (I-PRESERVE [Irbesartan in Heart Failure With Preserved Systolic Function], NCT00095238; TOPCAT [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist],...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Nov 15:S0735-1097(24)10420-2. doi: 10.1016/j.jacc.2024.11.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertension is common in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF), and current guidelines recommend treating systolic blood pressure (SBP) to a target &lt;130 mm Hg. However, data supporting treatment to this target are limited. Additionally, pulse pressure (PP), a marker of aortic stiffness, has been associated with increased risk of cardiovascular events, but its prognostic impact in HFpEF has not been extensively studied.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to explore the impact of baseline SBP and PP on cardiovascular outcomes in patients with HFmrEF or HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The I-PRESERVE (Irbesartan in Heart Failure With Preserved Ejection Fraction), TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist)-Americas, PARAGON-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin-Receptor Blocker Global Outcomes in HF With Preserved Ejection Fraction), and DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trials were global, randomized clinical trials testing irbesartan, spironolactone, sacubitril/valsartan, and dapagliflozin, respectively, against either a placebo or an active comparator (valsartan, in PARAGON-HF), in patients with heart failure and a left ventricular ejection fraction ≥40% (in DELIVER) or ≥45% (in the other trials). The relationship between continuous baseline SBP and PP, and the primary endpoint (first heart failure hospitalization or cardiovascular death) was analyzed with restricted cubic splines. We further evaluated the prognostic impact of SBP categories (&lt;120, 120-129, 130-139, and ≥140 mm Hg) and PP quartiles on the primary endpoint.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 16,950 patients (mean age 71 ± 9 years; 49% male; mean SBP 131 ± 15 mm Hg; mean PP 55 ± 14 mm Hg) were included. The relationship between SBP and the primary endpoint was J-shaped, with the lowest risk at 120 to 130 mm Hg. A similar pattern was found for PP, with the lowest risk at 50 to 60 mm Hg. The highest SBP category (reference: 120-129 mm Hg) and PP quartile (reference: 46-54 mm Hg) were associated with a higher risk of the primary outcome (HR: 1.22; 95% CI: 1.10-1.34 and HR: 1.22; 95% CI: 1.11-1.34, respectively). Higher PP was associated with greater cardiovascular risk, regardless of SBP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our analysis of a large pooled dataset from 4 clinical trials, including >;16,900 patients with HFmrEF/HFpEF, indicates a J-shaped relationship between both SBP and PP and cardiovascular risk. The lowest risk was observed at SBP levels between 120 and 130 mm Hg and PP values between 50 and 60 mm Hg (I-PRESERVE [Irbesartan in Heart Failure With Preserved Systolic Function], NCT00095238; TOPCAT [Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist], NCT00094302; PARAGON-HF [Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction], NCT01920711; DELIVER [Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure], NCT03619213).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39745404/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39745404</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.007>10.1016/j.jacc.2024.11.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39745404</guid>
<pubDate>Thu, 02 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Henri Lu</dc:creator>
<dc:creator>Toru Kondo</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brendon L Neuen</dc:creator>
<dc:creator>Iris E Beldhuis</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Finnian R Mc Causland</dc:creator>
<dc:creator>Inder S Anand</dc:creator>
<dc:creator>Marc A Pfeffer</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Michael R Zile</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:date>2025-01-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Systolic Blood Pressure and Pulse Pressure in Heart Failure: Pooled Participant-Level Analysis of 4 Trials</dc:title>
<dc:identifier>pmid:39745404</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.007</dc:identifier>
</item>
<item>
<title>The spleen in ischaemic heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39743566/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Ischaemic heart disease is a consequence of coronary atherosclerosis, and atherosclerosis is a systemic inflammatory disease. The spleen releases various immune cells in temporally distinct patterns. Neutrophils, monocytes, macrophages, B cells and T cells execute innate and adaptive immune processes in the coronary atherosclerotic plaque and in the ischaemic myocardium. Prolonged inflammation contributes to ischaemic heart failure. The spleen is also a target of neuromodulation through vagal,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 2. doi: 10.1038/s41569-024-01114-x. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Ischaemic heart disease is a consequence of coronary atherosclerosis, and atherosclerosis is a systemic inflammatory disease. The spleen releases various immune cells in temporally distinct patterns. Neutrophils, monocytes, macrophages, B cells and T cells execute innate and adaptive immune processes in the coronary atherosclerotic plaque and in the ischaemic myocardium. Prolonged inflammation contributes to ischaemic heart failure. The spleen is also a target of neuromodulation through vagal, sympathetic and sensory nerve activation. Efferent vagal activation and subsequent activation of the noradrenergic splenic nerve activate β<sub>2</sub>-adrenergic receptors on splenic T cells, which release acetylcholine that ultimately results in attenuation of cytokine secretion from splenic macrophages. Coeliac vagal nerve activation increases splenic sympathetic nerve activity and drives the release of T cells, a process that depends on placental growth factor. Activation of the vagosplenic axis protects acutely from ischaemia-reperfusion injury during auricular tragus vagal stimulation and remote ischaemic conditioning. Splenectomy abrogates all these deleterious and beneficial actions on the cardiovascular system. The aggregate effect of splenectomy in humans is a long-term increase in mortality from ischaemic heart disease. The spleen has been appreciated as an important immune organ for inflammatory processes in atherosclerosis, myocardial infarction and heart failure, whereas its complex interaction with circulating blood factors and with the autonomic and somatic nervous systems, as well as its role in cardioprotection, have emerged only in the past decade. In this Review, we describe this newly identified cardioprotective function of the spleen and highlight the potential for translating the findings to patients with ischaemic heart disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39743566/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39743566</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01114-x>10.1038/s41569-024-01114-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39743566</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Gerd Heusch</dc:creator>
<dc:creator>Petra Kleinbongard</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The spleen in ischaemic heart disease</dc:title>
<dc:identifier>pmid:39743566</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01114-x</dc:identifier>
</item>
<item>
<title>Apolipoprotein B-containing lipoproteins in atherogenesis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39743565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Apolipoprotein B (apoB) is the main structural protein of LDLs, triglyceride-rich lipoproteins and lipoprotein(a), and is crucial for their formation, metabolism and atherogenic properties. In this Review, we present insights into the role of apoB-containing lipoproteins in atherogenesis, with an emphasis on the mechanisms leading to plaque initiation and growth. LDL, the most abundant cholesterol-rich lipoprotein in plasma, is causally linked to atherosclerosis. LDL enters the artery wall by...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 2. doi: 10.1038/s41569-024-01111-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Apolipoprotein B (apoB) is the main structural protein of LDLs, triglyceride-rich lipoproteins and lipoprotein(a), and is crucial for their formation, metabolism and atherogenic properties. In this Review, we present insights into the role of apoB-containing lipoproteins in atherogenesis, with an emphasis on the mechanisms leading to plaque initiation and growth. LDL, the most abundant cholesterol-rich lipoprotein in plasma, is causally linked to atherosclerosis. LDL enters the artery wall by transcytosis and, in vulnerable regions, is retained in the subendothelial space by binding to proteoglycans via specific sites on apoB. A maladaptive response ensues. This response involves modification of LDL particles, which promotes LDL retention and the release of bioactive lipid products that trigger inflammatory responses in vascular cells, as well as adaptive immune responses. Resident and recruited macrophages take up modified LDL, leading to foam cell formation and ultimately cell death due to inadequate cellular lipid handling. Accumulation of dead cells and cholesterol crystallization are hallmarks of the necrotic core of atherosclerotic plaques. Other apoB-containing lipoproteins, although less abundant, have substantially greater atherogenicity per particle than LDL. These lipoproteins probably contribute to atherogenesis in a similar way to LDL but might also induce additional pathogenic mechanisms. Several targets for intervention to reduce the rate of atherosclerotic lesion initiation and progression have now been identified, including lowering plasma lipoprotein levels and modulating the maladaptive responses in the artery wall.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39743565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39743565</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01111-0>10.1038/s41569-024-01111-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39743565</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jan Borén</dc:creator>
<dc:creator>Chris J Packard</dc:creator>
<dc:creator>Christoph J Binder</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Apolipoprotein B-containing lipoproteins in atherogenesis</dc:title>
<dc:identifier>pmid:39743565</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01111-0</dc:identifier>
</item>
<item>
<title>Functional diversity of cardiac macrophages in health and disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39743564/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Macrophages make up a substantial portion of the stromal compartment of the heart in health and disease. In the past decade, the origins of these cardiac macrophages have been established as two broad populations derived from either embryonic or definitive haematopoiesis and that can be distinguished by the expression of CC-motif chemokine receptor 2 (CCR2). These cardiac macrophage populations are transcriptionally distinct and have differing cell surface markers and divergent roles in cardiac...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 2. doi: 10.1038/s41569-024-01109-8. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Macrophages make up a substantial portion of the stromal compartment of the heart in health and disease. In the past decade, the origins of these cardiac macrophages have been established as two broad populations derived from either embryonic or definitive haematopoiesis and that can be distinguished by the expression of CC-motif chemokine receptor 2 (CCR2). These cardiac macrophage populations are transcriptionally distinct and have differing cell surface markers and divergent roles in cardiac homeostasis and disease. Embryonic-derived CCR2<sup>-</sup> macrophages are a tissue-resident population that participates in tissue development, repair and maintenance, whereas CCR2<sup>+</sup> macrophages are derived from definitive haematopoiesis and contribute to inflammation and tissue damage. Studies from the past 5 years have leveraged single-cell RNA sequencing technologies to expand our understanding of cardiac macrophage diversity, particularly of the monocyte-derived macrophage populations that reside in the injured and diseased heart. Emerging technologies in spatial transcriptomics have enabled the identification of distinct disease-associated cellular neighbourhoods consisting of macrophages, other immune cells and fibroblasts, highlighting the involvement of macrophages in cell-cell communication. Together, these discoveries lend new insights into the role of specific macrophage populations in the pathogenesis of cardiac disease, which can pave the way for the identification of new therapeutic targets and the development of diagnostic tools. In this Review, we discuss the developmental origin of cardiac macrophages and describe newly identified cell states and associated cellular neighbourhoods in the steady state and injury settings. We also discuss various contributions and effector functions of cardiac macrophages in homeostasis and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39743564/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39743564</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01109-8>10.1038/s41569-024-01109-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39743564</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Steven Yang</dc:creator>
<dc:creator>Vinay Penna</dc:creator>
<dc:creator>Kory J Lavine</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Functional diversity of cardiac macrophages in health and disease</dc:title>
<dc:identifier>pmid:39743564</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01109-8</dc:identifier>
</item>
<item>
<title>Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39743563/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Computed tomography coronary angiography provides a non-invasive evaluation of coronary artery disease that includes phenotyping of atherosclerotic plaques and the surrounding perivascular adipose tissue (PVAT). Image analysis techniques have been developed to quantify atherosclerotic plaque burden and morphology as well as the associated PVAT attenuation, and emerging radiomic approaches can add further contextual information. PVAT attenuation might provide a novel measure of vascular health...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 2. doi: 10.1038/s41569-024-01110-1. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Computed tomography coronary angiography provides a non-invasive evaluation of coronary artery disease that includes phenotyping of atherosclerotic plaques and the surrounding perivascular adipose tissue (PVAT). Image analysis techniques have been developed to quantify atherosclerotic plaque burden and morphology as well as the associated PVAT attenuation, and emerging radiomic approaches can add further contextual information. PVAT attenuation might provide a novel measure of vascular health that could be indicative of the pathogenetic processes implicated in atherosclerosis such as inflammation, fibrosis or increased vascularity. Bidirectional signalling between the coronary artery and adjacent PVAT has been hypothesized to contribute to coronary artery disease progression and provide a potential novel measure of the risk of future cardiovascular events. However, despite the development of more advanced radiomic and artificial intelligence-based algorithms, studies involving large datasets suggest that the measurement of PVAT attenuation contributes only modest additional predictive discrimination to standard cardiovascular risk scores. In this Review, we explore the pathobiology of coronary atherosclerotic plaques and PVAT, describe their phenotyping with computed tomography coronary angiography, and discuss potential future applications in clinical risk prediction and patient management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39743563/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39743563</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01110-1>10.1038/s41569-024-01110-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39743563</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Kajetan Grodecki</dc:creator>
<dc:creator>Jolien Geers</dc:creator>
<dc:creator>Jacek Kwiecinski</dc:creator>
<dc:creator>Andrew Lin</dc:creator>
<dc:creator>Leandro Slipczuk</dc:creator>
<dc:creator>Piotr J Slomka</dc:creator>
<dc:creator>Marc R Dweck</dc:creator>
<dc:creator>Nitesh Nerlekar</dc:creator>
<dc:creator>Michelle C Williams</dc:creator>
<dc:creator>Daniel Berman</dc:creator>
<dc:creator>Thomas Marwick</dc:creator>
<dc:creator>David E Newby</dc:creator>
<dc:creator>Damini Dey</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis</dc:title>
<dc:identifier>pmid:39743563</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01110-1</dc:identifier>
</item>
<item>
<title>Haematometabolism rewiring in atherosclerotic cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39743562/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Atherosclerotic cardiovascular diseases are the most frequent cause of death worldwide. The clinical complications of atherosclerosis are closely linked to the haematopoietic and immune systems, which maintain homeostatic functions and vital processes in the body. The nodes linking metabolism and inflammation are receiving increasing attention because they are inextricably linked to inflammatory manifestations of non-communicable diseases, including atherosclerosis. Although metabolism and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 2. doi: 10.1038/s41569-024-01108-9. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atherosclerotic cardiovascular diseases are the most frequent cause of death worldwide. The clinical complications of atherosclerosis are closely linked to the haematopoietic and immune systems, which maintain homeostatic functions and vital processes in the body. The nodes linking metabolism and inflammation are receiving increasing attention because they are inextricably linked to inflammatory manifestations of non-communicable diseases, including atherosclerosis. Although metabolism and inflammation are essential to survival and involve all tissues, we still know little about how these processes influence each other. In an effort to understand these mechanisms, in this Review we explore whether and how potent cardiovascular risk factors and metabolic modifiers of atherosclerosis influence the molecular and cellular machinery of 'haematometabolism' (metabolic-dependent haematopoietic stem cell skewing) and 'efferotabolism' (metabolic-dependent efferocyte reprogramming). These changes might ultimately propagate a quantitative and qualitative drift of the macrophage supply chain and affect the clinical manifestations of atherosclerosis. Refining our understanding of the different metabolic requirements of these processes could open the possibility of developing therapeutics targeting haematometabolism that, in conjunction with improved dietary habits, help rebalance and promote efficient haematopoiesis and efferocytosis and decrease the risk of atherosclerosis complications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39743562/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39743562</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01108-9>10.1038/s41569-024-01108-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39743562</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Laurent Yvan-Charvet</dc:creator>
<dc:creator>Thibault Barouillet</dc:creator>
<dc:creator>Coraline Borowczyk</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Haematometabolism rewiring in atherosclerotic cardiovascular disease</dc:title>
<dc:identifier>pmid:39743562</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01108-9</dc:identifier>
</item>
<item>
<title>Renal denervation for hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39743561/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Innovative therapies for hypertension are desperately needed given the rising prevalence and falling rates of control of hypertension despite an abundance of available medical therapies. Procedural interventions lower blood pressure without depending on adherence to medications, and endovascular renal denervation (RDN) is the interventional procedure with the best evidence base for the treatment of hypertension. After nearly two decades of study, with major refinements to devices, technique and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 2. doi: 10.1038/s41569-024-01104-z. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Innovative therapies for hypertension are desperately needed given the rising prevalence and falling rates of control of hypertension despite an abundance of available medical therapies. Procedural interventions lower blood pressure without depending on adherence to medications, and endovascular renal denervation (RDN) is the interventional procedure with the best evidence base for the treatment of hypertension. After nearly two decades of study, with major refinements to devices, technique and trial design, two different systems for RDN received approval from the FDA in late 2023 for the treatment of hypertension. These decisions were based on a portfolio of sham-controlled clinical trials demonstrating efficacy and safety of both radiofrequency and ultrasound RDN in treating patients across the spectrum of hypertension, including patients with mild disease taking no or one medication as well as those with moderate and truly resistant hypertension. In this Review, we begin by summarizing the background and scope of the global problem of hypertension control and explore the evolution and mechanism of RDN. We then detail early studies and randomized clinical trials demonstrating the efficacy and safety of RDN procedures, review international statements, and provide practical guidance on patient selection and implementation of RDN, including the crucial aspects of building a hypertension team and of involving patients in shared decision-making.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39743561/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39743561</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01104-z>10.1038/s41569-024-01104-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39743561</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Naomi D L Fisher</dc:creator>
<dc:creator>Ajay J Kirtane</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Renal denervation for hypertension</dc:title>
<dc:identifier>pmid:39743561</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01104-z</dc:identifier>
</item>
<item>
<title>Extracellular matrix in vascular homeostasis and disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39743560/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>The extracellular matrix is an essential component and constitutes a dynamic microenvironment of the vessel wall with an indispensable role in vascular homeostasis and disease. From early development through to ageing, the vascular extracellular matrix undergoes various biochemical and biomechanical alterations in response to diverse environmental cues and exerts precise regulatory control over vessel remodelling. Advances in novel technologies that enable the comprehensive evaluation of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 2. doi: 10.1038/s41569-024-01103-0. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The extracellular matrix is an essential component and constitutes a dynamic microenvironment of the vessel wall with an indispensable role in vascular homeostasis and disease. From early development through to ageing, the vascular extracellular matrix undergoes various biochemical and biomechanical alterations in response to diverse environmental cues and exerts precise regulatory control over vessel remodelling. Advances in novel technologies that enable the comprehensive evaluation of extracellular matrix components and cell-matrix interactions have led to the emergence of therapeutic strategies that specifically target this fine-tuned network. In this Review, we explore various aspects of extracellular matrix biology in vascular development, disorders and ageing, emphasizing the effect of the extracellular matrix on disease initiation and progression. Additionally, we provide an overview of the potential therapeutic implications of targeting the extracellular matrix microenvironment in vascular diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39743560/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39743560</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01103-0>10.1038/s41569-024-01103-0</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39743560</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Lu Zhang</dc:creator>
<dc:creator>Jing Zhou</dc:creator>
<dc:creator>Wei Kong</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Extracellular matrix in vascular homeostasis and disease</dc:title>
<dc:identifier>pmid:39743560</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01103-0</dc:identifier>
</item>
<item>
<title>Transplantation of gasdermin pores by extracellular vesicles propagates pyroptosis to bystander cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39742811/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Pyroptosis mediated by gasdermins (GSDMs) plays crucial roles in infection and inflammation. Pyroptosis triggers the release of inflammatory molecules, including damage-associated molecular patterns (DAMPs). However, the consequences of pyroptosis-especially beyond interleukin (IL)-1 cytokines and DAMPs-that govern inflammation are poorly defined. Here, we show intercellular propagation of pyroptosis from dying cells to bystander cells in vitro and in vivo. We identified extracellular vesicles...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 26:S0092-8674(24)01334-5. doi: 10.1016/j.cell.2024.11.018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Pyroptosis mediated by gasdermins (GSDMs) plays crucial roles in infection and inflammation. Pyroptosis triggers the release of inflammatory molecules, including damage-associated molecular patterns (DAMPs). However, the consequences of pyroptosis-especially beyond interleukin (IL)-1 cytokines and DAMPs-that govern inflammation are poorly defined. Here, we show intercellular propagation of pyroptosis from dying cells to bystander cells in vitro and in vivo. We identified extracellular vesicles (EVs) released by pyroptotic cells as the propagator of lytic death to naive cells, promoting inflammation. DNA-PAINT super-resolution and immunoelectron microscopy revealed GSDMD pore structures on EVs released by pyroptotic cells. Importantly, pyroptotic EVs transplant GSDMD pores on the plasma membrane of bystander cells and kill them. Overall, we demonstrate that cell-to-cell vesicular transplantation of GSDMD pores disseminates pyroptosis, revealing a domino-like effect governing disease-associated bystander cell death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39742811/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39742811</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.018>10.1016/j.cell.2024.11.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39742811</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Skylar S Wright</dc:creator>
<dc:creator>Puja Kumari</dc:creator>
<dc:creator>Víctor Fraile-Ágreda</dc:creator>
<dc:creator>Chengliang Wang</dc:creator>
<dc:creator>Sonia Shivcharan</dc:creator>
<dc:creator>Shirin Kappelhoff</dc:creator>
<dc:creator>Eleonora G Margheritis</dc:creator>
<dc:creator>Alyssa Matz</dc:creator>
<dc:creator>Swathy O Vasudevan</dc:creator>
<dc:creator>Ignacio Rubio</dc:creator>
<dc:creator>Michael Bauer</dc:creator>
<dc:creator>Beiyan Zhou</dc:creator>
<dc:creator>Sivapriya Kailasan Vanaja</dc:creator>
<dc:creator>Katia Cosentino</dc:creator>
<dc:creator>Jianbin Ruan</dc:creator>
<dc:creator>Vijay A Rathinam</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Transplantation of gasdermin pores by extracellular vesicles propagates pyroptosis to bystander cells</dc:title>
<dc:identifier>pmid:39742811</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.018</dc:identifier>
</item>
<item>
<title>The human zinc-binding cysteine proteome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39742810/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Zinc is an essential micronutrient that regulates a wide range of physiological processes, most often through zinc binding to protein cysteine residues. Despite being critical for modulation of protein function, the cysteine sites in the majority of the human proteome that are subject to zinc binding remain undefined. Here, we develop ZnCPT, a deep and quantitative mapping of the zinc-binding cysteine proteome. We define 6,173 zinc-binding cysteines, uncovering protein families across major...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 26:S0092-8674(24)01341-2. doi: 10.1016/j.cell.2024.11.025. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Zinc is an essential micronutrient that regulates a wide range of physiological processes, most often through zinc binding to protein cysteine residues. Despite being critical for modulation of protein function, the cysteine sites in the majority of the human proteome that are subject to zinc binding remain undefined. Here, we develop ZnCPT, a deep and quantitative mapping of the zinc-binding cysteine proteome. We define 6,173 zinc-binding cysteines, uncovering protein families across major domains of biology that are subject to constitutive or inducible zinc binding. ZnCPT enables systematic discovery of zinc-regulated structural, enzymatic, and allosteric functional domains. On this basis, we identify 52 cancer genetic dependencies subject to zinc binding and nominate malignancies sensitive to zinc-induced cytotoxicity. We discover a mechanism of zinc regulation over glutathione reductase (GSR), which drives cell death in GSR-dependent lung cancers. We provide ZnCPT as a resource for understanding mechanisms of zinc regulation of protein function.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39742810/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39742810</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.025>10.1016/j.cell.2024.11.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39742810</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Nils Burger</dc:creator>
<dc:creator>Melanie J Mittenbühler</dc:creator>
<dc:creator>Haopeng Xiao</dc:creator>
<dc:creator>Sanghee Shin</dc:creator>
<dc:creator>Shelley M Wei</dc:creator>
<dc:creator>Erik K Henze</dc:creator>
<dc:creator>Sebastian Schindler</dc:creator>
<dc:creator>Sepideh Mehravar</dc:creator>
<dc:creator>David M Wood</dc:creator>
<dc:creator>Jonathan J Petrocelli</dc:creator>
<dc:creator>Yizhi Sun</dc:creator>
<dc:creator>Hans-Georg Sprenger</dc:creator>
<dc:creator>Pedro Latorre-Muro</dc:creator>
<dc:creator>Amanda L Smythers</dc:creator>
<dc:creator>Luiz H M Bozi</dc:creator>
<dc:creator>Narek Darabedian</dc:creator>
<dc:creator>Yingde Zhu</dc:creator>
<dc:creator>Hyuk-Soo Seo</dc:creator>
<dc:creator>Sirano Dhe-Paganon</dc:creator>
<dc:creator>Jianwei Che</dc:creator>
<dc:creator>Edward T Chouchani</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The human zinc-binding cysteine proteome</dc:title>
<dc:identifier>pmid:39742810</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.025</dc:identifier>
</item>
<item>
<title>Global organelle profiling reveals subcellular localization and remodeling at proteome scale</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39742809/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Defining the subcellular distribution of all human proteins and their remodeling across cellular states remains a central goal in cell biology. Here, we present a high-resolution strategy to map subcellular organization using organelle immunocapture coupled to mass spectrometry. We apply this workflow to a cell-wide collection of membranous and membraneless compartments. A graph-based analysis assigns the subcellular localization of over 7,600 proteins, defines spatial networks, and uncovers...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 26:S0092-8674(24)01344-8. doi: 10.1016/j.cell.2024.11.028. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Defining the subcellular distribution of all human proteins and their remodeling across cellular states remains a central goal in cell biology. Here, we present a high-resolution strategy to map subcellular organization using organelle immunocapture coupled to mass spectrometry. We apply this workflow to a cell-wide collection of membranous and membraneless compartments. A graph-based analysis assigns the subcellular localization of over 7,600 proteins, defines spatial networks, and uncovers interconnections between cellular compartments. Our approach can be deployed to comprehensively profile proteome remodeling during cellular perturbation. By characterizing the cellular landscape following HCoV-OC43 viral infection, we discover that many proteins are regulated by changes in their spatial distribution rather than by changes in abundance. Our results establish that proteome-wide analysis of subcellular remodeling provides key insights for elucidating cellular responses, uncovering an essential role for ferroptosis in OC43 infection. Our dataset can be explored at organelles.czbiohub.org.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39742809/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39742809</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.028>10.1016/j.cell.2024.11.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39742809</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Marco Y Hein</dc:creator>
<dc:creator>Duo Peng</dc:creator>
<dc:creator>Verina Todorova</dc:creator>
<dc:creator>Frank McCarthy</dc:creator>
<dc:creator>Kibeom Kim</dc:creator>
<dc:creator>Chad Liu</dc:creator>
<dc:creator>Laura Savy</dc:creator>
<dc:creator>Camille Januel</dc:creator>
<dc:creator>Rodrigo Baltazar-Nunez</dc:creator>
<dc:creator>Madhurya Sekhar</dc:creator>
<dc:creator>Shivanshi Vaid</dc:creator>
<dc:creator>Sophie Bax</dc:creator>
<dc:creator>Madhuri Vangipuram</dc:creator>
<dc:creator>James Burgess</dc:creator>
<dc:creator>Leila Njoya</dc:creator>
<dc:creator>Eileen Wang</dc:creator>
<dc:creator>Ivan E Ivanov</dc:creator>
<dc:creator>Janie R Byrum</dc:creator>
<dc:creator>Soorya Pradeep</dc:creator>
<dc:creator>Carlos G Gonzalez</dc:creator>
<dc:creator>Yttria Aniseia</dc:creator>
<dc:creator>Joseph S Creery</dc:creator>
<dc:creator>Aidan H McMorrow</dc:creator>
<dc:creator>Sara Sunshine</dc:creator>
<dc:creator>Serena Yeung-Levy</dc:creator>
<dc:creator>Brian C DeFelice</dc:creator>
<dc:creator>Shalin B Mehta</dc:creator>
<dc:creator>Daniel N Itzhak</dc:creator>
<dc:creator>Joshua E Elias</dc:creator>
<dc:creator>Manuel D Leonetti</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Global organelle profiling reveals subcellular localization and remodeling at proteome scale</dc:title>
<dc:identifier>pmid:39742809</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.028</dc:identifier>
</item>
<item>
<title>DNA end sensing and cleavage by the Shedu anti-phage defense system</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39742808/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>The detection of molecular patterns associated with invading pathogens is a hallmark of innate immune systems. Prokaryotes deploy sophisticated host defense mechanisms in innate anti-phage immunity. Shedu is a single-component defense system comprising a putative nuclease SduA. Here, we report cryoelectron microscopy (cryo-EM) structures of apo- and double-stranded DNA (dsDNA)-bound tetrameric SduA assemblies, revealing that the N-terminal domains of SduA form a clamp that recognizes free DNA...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 30:S0092-8674(24)01346-1. doi: 10.1016/j.cell.2024.11.030. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The detection of molecular patterns associated with invading pathogens is a hallmark of innate immune systems. Prokaryotes deploy sophisticated host defense mechanisms in innate anti-phage immunity. Shedu is a single-component defense system comprising a putative nuclease SduA. Here, we report cryoelectron microscopy (cryo-EM) structures of apo- and double-stranded DNA (dsDNA)-bound tetrameric SduA assemblies, revealing that the N-terminal domains of SduA form a clamp that recognizes free DNA ends. End binding positions the DNA over the PD-(D/E)XK nuclease domain, resulting in dsDNA nicking at a fixed distance from the 5' end. The end-directed DNA nicking activity of Shedu prevents propagation of linear DNA in vivo. Finally, we show that phages escape Shedu immunity by suppressing their recombination-dependent DNA replication pathway. Taken together, these results define the antiviral mechanism of Shedu systems, underlining the paradigm that recognition of pathogen-specific nucleic acid structures is a conserved feature of innate immunity across all domains of life.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39742808/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39742808</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.030>10.1016/j.cell.2024.11.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39742808</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Luuk Loeff</dc:creator>
<dc:creator>Alexander Walter</dc:creator>
<dc:creator>Gian Tizio Rosalen</dc:creator>
<dc:creator>Martin Jinek</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>DNA end sensing and cleavage by the Shedu anti-phage defense system</dc:title>
<dc:identifier>pmid:39742808</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.030</dc:identifier>
</item>
<item>
<title>Configuration of electrical synapses filters sensory information to drive behavioral choices</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39742807/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Synaptic configurations underpin how the nervous system processes sensory information to produce a behavioral response. This is best understood for chemical synapses, and we know far less about how electrical synaptic configurations modulate sensory information processing and context-specific behaviors. We discovered that innexin 1 (INX-1), a gap junction protein that forms electrical synapses, is required to deploy context-specific behavioral strategies underlying thermotaxis behavior in C....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 26:S0092-8674(24)01378-3. doi: 10.1016/j.cell.2024.11.037. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Synaptic configurations underpin how the nervous system processes sensory information to produce a behavioral response. This is best understood for chemical synapses, and we know far less about how electrical synaptic configurations modulate sensory information processing and context-specific behaviors. We discovered that innexin 1 (INX-1), a gap junction protein that forms electrical synapses, is required to deploy context-specific behavioral strategies underlying thermotaxis behavior in C. elegans. Within this well-defined circuit, INX-1 couples two bilaterally symmetric interneurons to integrate sensory information during migratory behavior across temperature gradients. In inx-1 mutants, uncoupled interneurons display increased excitability and responses to subthreshold sensory stimuli due to increased membrane resistance and reduced membrane capacitance, resulting in abnormal responses that extend run durations and trap the animals in context-irrelevant tracking of isotherms. Thus, a conserved configuration of electrical synapses enables differential processing of sensory information to deploy context-specific behavioral strategies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39742807/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39742807</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.037>10.1016/j.cell.2024.11.037</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39742807</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Agustin Almoril-Porras</dc:creator>
<dc:creator>Ana C Calvo</dc:creator>
<dc:creator>Longgang Niu</dc:creator>
<dc:creator>Jonathan Beagan</dc:creator>
<dc:creator>Malcom Díaz García</dc:creator>
<dc:creator>Josh D Hawk</dc:creator>
<dc:creator>Ahmad Aljobeh</dc:creator>
<dc:creator>Elias M Wisdom</dc:creator>
<dc:creator>Ivy Ren</dc:creator>
<dc:creator>Zhao-Wen Wang</dc:creator>
<dc:creator>Daniel A Colón-Ramos</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Configuration of electrical synapses filters sensory information to drive behavioral choices</dc:title>
<dc:identifier>pmid:39742807</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.037</dc:identifier>
</item>
<item>
<title>A spatially resolved multi-omic single-cell atlas of soybean development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39742806/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Cis-regulatory elements (CREs) precisely control spatiotemporal gene expression in cells. Using a spatially resolved single-cell atlas of gene expression with chromatin accessibility across ten soybean tissues, we identified 103 distinct cell types and 303,199 accessible chromatin regions (ACRs). Nearly 40% of the ACRs showed cell-type-specific patterns and were enriched for transcription factor (TF) motifs defining diverse cell identities. We identified de novo enriched TF motifs and explored...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 24:S0092-8674(24)01273-X. doi: 10.1016/j.cell.2024.10.050. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cis-regulatory elements (CREs) precisely control spatiotemporal gene expression in cells. Using a spatially resolved single-cell atlas of gene expression with chromatin accessibility across ten soybean tissues, we identified 103 distinct cell types and 303,199 accessible chromatin regions (ACRs). Nearly 40% of the ACRs showed cell-type-specific patterns and were enriched for transcription factor (TF) motifs defining diverse cell identities. We identified de novo enriched TF motifs and explored the conservation of gene regulatory networks underpinning legume symbiotic nitrogen fixation. With comprehensive developmental trajectories for endosperm and embryo, we uncovered the functional transition of the three sub-cell types of endosperm, identified 13 sucrose transporters sharing the DNA binding with one finger 11 (DOF11) motif that were co-upregulated in late peripheral endosperm, and identified key embryo cell-type specification regulators during embryogenesis, including a homeobox TF that promotes cotyledon parenchyma identity. This resource provides a valuable foundation for analyzing gene regulatory programs in soybean cell types across tissues and life stages.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39742806/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39742806</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.050>10.1016/j.cell.2024.10.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39742806</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Xuan Zhang</dc:creator>
<dc:creator>Ziliang Luo</dc:creator>
<dc:creator>Alexandre P Marand</dc:creator>
<dc:creator>Haidong Yan</dc:creator>
<dc:creator>Hosung Jang</dc:creator>
<dc:creator>Sohyun Bang</dc:creator>
<dc:creator>John P Mendieta</dc:creator>
<dc:creator>Mark A A Minow</dc:creator>
<dc:creator>Robert J Schmitz</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A spatially resolved multi-omic single-cell atlas of soybean development</dc:title>
<dc:identifier>pmid:39742806</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.050</dc:identifier>
</item>
<item>
<title>Nucleocapsid assembly drives Ebola viral factory maturation and dispersion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39742805/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>Replication and genome encapsidation of many negative-sense RNA viruses take place in virus-induced membraneless organelles termed viral factories (VFs). Although liquid properties of VFs are believed to control the transition from genome replication to nucleocapsid (NC) assembly, VF maturation and interactions with the cellular environment remain elusive. Here, we apply in situ cryo-correlative light and electron tomography to follow NC assembly and changes in VF morphology and their liquid...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Dec 14:S0092-8674(24)01340-0. doi: 10.1016/j.cell.2024.11.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Replication and genome encapsidation of many negative-sense RNA viruses take place in virus-induced membraneless organelles termed viral factories (VFs). Although liquid properties of VFs are believed to control the transition from genome replication to nucleocapsid (NC) assembly, VF maturation and interactions with the cellular environment remain elusive. Here, we apply in situ cryo-correlative light and electron tomography to follow NC assembly and changes in VF morphology and their liquid properties during Ebola virus infection. We show that viral NCs transition from loosely packed helical assemblies in early VFs to compact cylinders that arrange into highly organized parallel bundles later in infection. Early VFs associate with intermediate filaments and are devoid of other host material but become progressively accessible to cellular components. Our data suggest that this process is coupled to VF solidification, loss of sphericity, and dispersion and promotes cytoplasmic exposure of NCs to facilitate their transport to budding sites.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39742805/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39742805</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.11.024>10.1016/j.cell.2024.11.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39742805</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Melina Vallbracht</dc:creator>
<dc:creator>Bianca S Bodmer</dc:creator>
<dc:creator>Konstantin Fischer</dc:creator>
<dc:creator>Jana Makroczyova</dc:creator>
<dc:creator>Sophie L Winter</dc:creator>
<dc:creator>Lisa Wendt</dc:creator>
<dc:creator>Moritz Wachsmuth-Melm</dc:creator>
<dc:creator>Thomas Hoenen</dc:creator>
<dc:creator>Petr Chlanda</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Nucleocapsid assembly drives Ebola viral factory maturation and dispersion</dc:title>
<dc:identifier>pmid:39742805</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.11.024</dc:identifier>
</item>
<item>
<title>BRISC-Mediated PPM1B-K63 Deubiquitination and Subsequent TGF-β Pathway Activation Promote High-Fat/High-Sucrose Diet-Induced Arterial Stiffness</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39742393/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250102131440&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: We elucidated the PPM1B deubiquitination mechanisms and highlighted a potential therapeutic target for metabolic syndrome-related arterial stiffness.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 1. doi: 10.1161/CIRCRESAHA.124.325590. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Metabolic syndrome heightens cardiovascular disease risk primarily through increased arterial stiffness. We previously demonstrated the involvement of YAP (Yes-associated protein) in high-fat/high-sucrose diet (HFHSD)-induced arterial stiffness via modulation of PPM1B (protein phosphatase Mg<sup>2+</sup>/Mn<sup>2+</sup>-dependent 1B)-lysine63 (K63) deubiquitination. In this study, we aimed to elucidate the role and mechanisms underlying PPM1B deubiquitination in HFHSD-induced arterial stiffness.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Enzymes governing PPM1B deubiquitination were identified through siRNA screening and mass spectrometry. Glutathione S-transferase pull-down, coimmunoprecipitation, protein purification, and immunofluorescence were used to explore the mechanism underlying PPM1B deubiquitination. Doppler ultrasound was used to evaluate HFHSD-induced arterial stiffness in mice, and telemetry was used to record pulsatile (systolic and diastolic) blood pressure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Smooth muscle cell-specific PPM1B overexpression attenuated HFHSD-induced arterial stiffness in mice in a PPM1B-K326-K63-linked polyubiquitination-dependent manner. Mechanistically, ABRO1 (Abraxas brother 1; a core BRCC36 [BRCA1/BRCA2-containing complex subunit 36] isopeptidase complex component) directly bound YAP and underwent liquid-liquid phase separation with YAP and PPM1B in a YAP-dependent manner, which in turn promoted PPM1B deubiquitination. Furthermore, smooth muscle cell-specific <i>Abro1</i>-knockout mice and <i>Brcc3</i>-knockout mice showed attenuated HFHSD-induced arterial stiffness and activation of transforming growth factor-β-Smad signaling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We elucidated the PPM1B deubiquitination mechanisms and highlighted a potential therapeutic target for metabolic syndrome-related arterial stiffness.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39742393/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250102131440&v=2.18.0.post9+e462414">39742393</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325590>10.1161/CIRCRESAHA.124.325590</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39742393</guid>
<pubDate>Wed, 01 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Yanan Liu</dc:creator>
<dc:creator>Mengke Li</dc:creator>
<dc:creator>Zhipeng Chen</dc:creator>
<dc:creator>Min Zuo</dc:creator>
<dc:creator>Kaiwen Bao</dc:creator>
<dc:creator>Ziyan Zhao</dc:creator>
<dc:creator>Meng Yan</dc:creator>
<dc:creator>Yongping Bai</dc:creator>
<dc:creator>Ding Ai</dc:creator>
<dc:creator>Hu Wang</dc:creator>
<dc:creator>Hongfeng Jiang</dc:creator>
<dc:date>2025-01-01</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>BRISC-Mediated PPM1B-K63 Deubiquitination and Subsequent TGF-β Pathway Activation Promote High-Fat/High-Sucrose Diet-Induced Arterial Stiffness</dc:title>
<dc:identifier>pmid:39742393</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325590</dc:identifier>
</item>





























</channel>
</rss>